J7683 HCPCS Level II code: Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
J7683 is the HCPCS code for “Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7683Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
Short description: Triamcinolone comp con
HCPCS · United States
Notes for J7683
As CMS prints them, with any note J7683 takes from the headings above it.
Note
- CMS processing note 0135: MEDICARE BENEFIT POLICY MANUAL, PUB 100.2, CHAPTER 15, SECTION 110.3 (100.02,15,110.3).
Medicare details
The indicators CMS publishes with J7683 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Drugs Administered through DME
- Added
- Jan 1, 2000
Where J7683 sits
- 1J codesDrugs administered other than orally
- 2Active code J7683Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7683 mean?
J7683 is the HCPCS code for “Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7683?
CMS lists J7683’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7683
All J codesJ7674Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mgJ7676Pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mgJ7677Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgramJ7680Terbutaline sulfate, inhalation solution, compounded product, administered through dme, concentrated form, per milligramJ7681Terbutaline sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7682Tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligramsJ7684Triamcinolone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7685Tobramycin, inhalation solution, compounded product, administered through dme, unit dose form, per 300 milligramsJ7686Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mgJ7699Noc drugs, inhalation solution administered through dmeJ7799Noc drugs, other than inhalation drugs, administered through dmeJ7999Compounded drug, not otherwise classified